Global Muscle Hypotonia Market, By Types (Acquired hypotonia and congenital hypotonia), Treatment (physiotherapy, occupational therapy, speech and language therapy, drugs), Diagnosis (physical examination, muscle biopsy), Route of Administration (Oral, Injectable and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, and Others) – Industry Trends and Forecast to 2030.
Muscle Hypotonia Market Analysis and Size
Hypotonia is generally present at birth and is often diagnosed in early infancy. There are several reasons for hypotonia in an infant. Many cases of hypotonia are congenital. Among the congenital hypotonias, central pathology accounts for most. These typically include hypoxic-ischemic encephalopathy or genetic abnormalities. Central hypotonia is noticed in around 60%-80% of cases. Rarely, hypotonia is caused by botulism infections or any contact with poisons or toxins. Though, the hypotonia often goes away after recovery.
Data Bridge Market Research analyses a growth rate in the muscle hypotonia market in the forecast period 2023-2030. The expected CAGR of the muscle hypotonia market is tend to be around 8.7% in the mentioned forecast period. The market was valued at USD 123.4 million in 2022, and it would grow up to USD 240.52 million by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Muscle Hypotonia Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Acquired hypotonia and congenital hypotonia), Treatment (physiotherapy, occupational therapy, speech and language therapy, drugs), Diagnosis (physical examination, muscle biopsy), Route of Administration (Oral, Injectable and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
LivaNova PLC (U.K.), EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), Boston Scientific Corporation (U.S.), Cyberonics, Inc. (U.S.), NeuroMetrix, Inc. (U.S.), ImThera Medical (U.S.), and Inspire Medical Systems, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Hypotonia also known as floppy baby syndrome that, means decreased muscle tone. It is mainly witnessed in children. Low-toned muscles contract very slowly in response to a stimulus, and as a result, contraction cannot be maintained for a longer period of time than normal muscle. Damage to the brain, spinal cord, nerves, or muscles can cause hypotonia. These damages can be the consequences of genetic, trauma, environmental factors, muscle, or central nervous system disorders.
Global Muscle Hypotonia Market Dynamics
Drivers
- Rising Prevalence of Musculoskeletal Issues
The growing prevalence of musculoskeletal problems and increasing customer awareness of their treatment and management enhance the market's growth. Structurally distinct medications are the recent technologically improved muscle hypotonias which are used to calm muscle spasms, discomfort, and hyperreflexia. This boosts the growth of the market.
- Growing Prevalence of Hypotonia
Central hypotonia is witnessed in up to 60%-80% of cases. Spinal muscular atrophy has an occurrence of 1 in 6,000 to 1 in 10,000 live births. In the USA, California, Pennsylvania, and Utah have a high prevalence of infant botulism, with around 50% of cases in California. This led to the growth of the market.
Opportunities
- Growing Prevalence of Lower Back Pain
As per the records of the WHO, the non-specific burden of lower back pain has increased significantly worldwide, which is expected at 60–70% in industrialized countries, whereas the one-year occurrence rate increased rate 15–45%, adult prevalence 5% per annum and mostly prevalence of lower back pain has seen in people above 35 years. Thus, this factor demands more drugs and, as a result, increases the market growth.
- Increased Demand of Varied Treatment Options
There are numerous treatment options that lead to the growth of the market. Rehabilitation, nutritional, and respiratory support are some of the major treatment options. Specific treatment can be provided in specific cases such as Pompe disease, wherein early enzyme replacement therapy can considerably improve the outcome. Thus, this leads to market expansion.
Restraints/Challenges
- Adverse Side-Effects of Muscle Hypotonias
There are severe side effects related to the drugs of muscle hypotonias, such as dizziness, dry mouth, tiredness, and depression which restrict the market growth.
- High Investment and Strict Regulatory Norms
The growth of the muscle hypotonia market is limited by several factors such as strict regulatory requirements and the risks related with the muscle hypotonias. Being a complex process, the use, separation, and development of raw materials for developing pharmaceutical and biopharmaceutical drugs demand professional and qualified personnel. Therefore, all these factors limit the growth of the demand for muscle hypotonia drugs.
This muscle hypotonia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the muscle hypotonia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Muscle Hypotonia Market Scope
The muscle hypotonia market is segmented on the basis of type, treatment, diagnosis, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Acquired hypotonia
- Congenital hypotonia
Treatment
- Physiotherapy
- Occupational Therapy
- Speech And Language Therapy
- Drugs
Diagnosis
- Physical Examination
- Muscle Biopsy
Route of Administration
- Oral
- Injectable
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Muscle Hypotonia Drugs Market Regional Analysis/Insights
The muscle hypotonia market is analyzed and market size insights and trends are provided by type, treatment, diagnosis, route of administration, end-user, distribution channel as referenced above.
The major countries covered in the muscle hypotonia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is considered to have the highest lucrative growth in the forecast period due to growing patient population, high healthcare expenditure, well-developed technology, and rise in government support for research & development in this region.
Asia-Pacific is dominating the market due to rapidly developing healthcare technology, huge patient population, and high healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Muscle Hypotonia Market Share Analysis
The muscle hypotonia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to muscle hypotonia market.
Key players operating in the muscle hypotonia market include:
- LivaNova PLC (U.K.)
- EnteroMedics Inc. (U.S.)
- ElectroCore Medical LLC (U.S.)
- Boston Scientific Corporation (U.S.)
- Cyberonics, Inc. (U.S.)
- NeuroMetrix, Inc. (U.S.)
- ImThera Medical (U.S.)
- Inspire Medical Systems, Inc. (U.S.)
SKU-